Richland WA, July 29, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK:RDGL), stock symbol reverts back to RDGL effective with the open of trading on Monday, July 29. As previously disclosed, the D at the end of the stock ticker is removed 20 business days following the completion of the reverse stock split that was completed on June 28, 2019.

Additionally, the University of Missouri is completing the final report on the IsoPet® therapy that was conducted over the last year. After receiving that report, we will submit it to the FDA and schedule a pre-submittal meeting to emphasize the key points of the completed test plan.

We are greatly encouraged that the tests demonstrate that IsoPet® was safe and effective. In particular, since the University of Missouri had both CT and PET, we were able to demonstrate the perfusion of IsoPet® into the tumor, which was one of the FDA's primary questions among others.

At this upcoming meeting we intend to refine the remaining testing needed to complete the pre-clinical requirements to write the Investigational Device Exemption, IDE. Obtaining IDE approval after submittal typically takes at least eight months.

Mike Korenko said "Our primary near-term emphasis it to expand our IsoPet® therapy commercially, while continuing to advance RadioGel™ within the FDA, with the goal of securing the IDE for human trials."

About Vivos Inc. (OTC:RDGL) >> Read Full Release